[go: up one dir, main page]

CL2012003075A1 - Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. - Google Patents

Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.

Info

Publication number
CL2012003075A1
CL2012003075A1 CL2012003075A CL2012003075A CL2012003075A1 CL 2012003075 A1 CL2012003075 A1 CL 2012003075A1 CL 2012003075 A CL2012003075 A CL 2012003075A CL 2012003075 A CL2012003075 A CL 2012003075A CL 2012003075 A1 CL2012003075 A1 CL 2012003075A1
Authority
CL
Chile
Prior art keywords
solution
pazopanib
stable
pharmaceutical composition
preparation
Prior art date
Application number
CL2012003075A
Other languages
English (en)
Inventor
Manish K Gupta
Original Assignee
Glaxo Wellcome Mfg Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Mfg Pte Ltd filed Critical Glaxo Wellcome Mfg Pte Ltd
Publication of CL2012003075A1 publication Critical patent/CL2012003075A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición farmacéutica en solución de pazopanib, estable y para uso oftálmico; método para la preparación de dicha solución.
CL2012003075A 2010-05-05 2012-10-31 Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. CL2012003075A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33171510P 2010-05-05 2010-05-05

Publications (1)

Publication Number Publication Date
CL2012003075A1 true CL2012003075A1 (es) 2013-03-08

Family

ID=44851507

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003075A CL2012003075A1 (es) 2010-05-05 2012-10-31 Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.

Country Status (27)

Country Link
US (3) US20120028918A1 (es)
EP (1) EP2566331B1 (es)
JP (1) JP5835717B2 (es)
KR (1) KR20130071434A (es)
CN (1) CN102970871A (es)
AR (1) AR081364A1 (es)
AU (1) AU2011247995B2 (es)
BR (1) BR112012028291A2 (es)
CA (1) CA2798386A1 (es)
CL (1) CL2012003075A1 (es)
CO (1) CO6640262A2 (es)
CR (1) CR20120556A (es)
DO (1) DOP2012000281A (es)
EA (1) EA201291168A1 (es)
ES (1) ES2519615T3 (es)
HK (1) HK1175947A1 (es)
IL (1) IL222751A0 (es)
MA (1) MA34286B1 (es)
MX (1) MX2012012837A (es)
NZ (1) NZ603411A (es)
PE (1) PE20130217A1 (es)
PH (1) PH12012502159A1 (es)
SG (1) SG185087A1 (es)
TW (1) TW201206908A (es)
UY (1) UY33367A (es)
WO (1) WO2011140343A1 (es)
ZA (1) ZA201208265B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
DK2600930T3 (da) 2010-08-05 2021-03-01 Forsight Vision4 Inc Injektionsapparat til lægemiddelafgivelse
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP3903733A1 (en) 2011-09-16 2021-11-03 ForSight Vision4, Inc. Fluid exchange apparatus
SG11201404888SA (en) * 2012-02-17 2014-09-26 Pharmacyclics Inc Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
JP2015513864A (ja) * 2012-03-08 2015-05-14 サムスン エレクトロニクス カンパニー リミテッド 無線通信システムでサービスを制御するための方法
WO2014152959A1 (en) * 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
ES2972168T3 (es) 2013-03-28 2024-06-11 Forsight Vision4 Inc Implante oftálmico para administración de sustancias terapéuticas
EP3039424B1 (en) 2013-08-28 2020-07-29 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
BR112017002466A2 (pt) * 2014-08-08 2017-12-05 Forsight Vision4 Inc formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação
RU2708958C2 (ru) 2014-11-10 2019-12-12 Форсайт Вижн4, Инк. Расширяемые устройства доставки лекарственных средств и способы использования
US11129900B2 (en) 2014-12-25 2021-09-28 Kyoto University Cytophilic peptide-fused high-density lipoprotein, and delivery of drug to posterior segment of eye by ocular installation of said fusion
WO2017176886A1 (en) 2016-04-05 2017-10-12 Forsight Vision4, Inc. Implantable ocular drug delivery devices
CN110769853B (zh) * 2017-04-17 2022-06-03 北京生命科学研究所 治疗雄性衰老
TWI770246B (zh) * 2017-08-02 2022-07-11 昊運股份有限公司 新穎化合物及包含其之醫藥組成物
SMT202300307T1 (it) * 2018-06-07 2023-11-13 Pfizer Formulazione acquosa che comprende 1-(4-{[4-(dimetilammino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5- triazin-2-il)fenil]urea.
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
US20240050429A1 (en) * 2022-08-10 2024-02-15 Qx Therapeutics, Inc. Pazopanib pharmaceutical composition, injection and preparation method and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20080293691A1 (en) * 2005-11-29 2008-11-27 Smithkline Beecham Corporation Treatment Method
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CA2650922C (en) * 2006-04-18 2015-09-29 Ekr Therapeutics, Inc. Pre-mixed, ready-to-use pharmaceutical compositions
MX2010004281A (es) * 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
WO2009097446A1 (en) * 2008-01-30 2009-08-06 Genentech, Inc. Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
KR20120049267A (ko) * 2009-07-16 2012-05-16 글락소 웰컴 매뉴팩쳐링 피티이 엘티디 치료 방법
US20120232102A1 (en) * 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
TW201201808A (en) * 2010-01-06 2012-01-16 Glaxo Wellcome Mfg Pte Ltd Treatment method
US20130023550A1 (en) * 2010-05-05 2013-01-24 Glaxo Wellcome Manufacturing Pte, Ltd Pharmaceutical compositions and methods of making same
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion

Also Published As

Publication number Publication date
AU2011247995B2 (en) 2014-07-31
CN102970871A (zh) 2013-03-13
AU2011247995A1 (en) 2012-12-13
CO6640262A2 (es) 2013-03-22
CA2798386A1 (en) 2011-11-10
MA34286B1 (fr) 2013-06-01
US20120028918A1 (en) 2012-02-02
ES2519615T3 (es) 2014-11-07
EA201291168A1 (ru) 2013-06-28
EP2566331A1 (en) 2013-03-13
HK1175947A1 (en) 2013-07-19
MX2012012837A (es) 2013-01-24
EP2566331B1 (en) 2014-09-03
PE20130217A1 (es) 2013-03-21
US20150231265A1 (en) 2015-08-20
PH12012502159A1 (en) 2013-02-04
US20110281901A1 (en) 2011-11-17
KR20130071434A (ko) 2013-06-28
SG185087A1 (en) 2012-12-28
ZA201208265B (en) 2013-07-31
JP5835717B2 (ja) 2015-12-24
BR112012028291A2 (pt) 2015-09-15
NZ603411A (en) 2014-10-31
WO2011140343A1 (en) 2011-11-10
UY33367A (es) 2011-10-31
TW201206908A (en) 2012-02-16
CR20120556A (es) 2013-02-20
DOP2012000281A (es) 2013-05-31
AR081364A1 (es) 2012-08-29
IL222751A0 (en) 2012-12-31
EP2566331A4 (en) 2013-09-18
JP2013525501A (ja) 2013-06-20

Similar Documents

Publication Publication Date Title
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CO6650338A2 (es) Antígenos de tuberculosis modificados
CR20130033A (es) Formulaciones de rifaximina y usos de las mismas
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
MY187874A (en) Antibody formulations
AR090923A1 (es) Anticuerpos anti-il-23
BR112013003825A2 (pt) conjugados, partículas, composições e métodos relacionados
PH12015500196A1 (en) Methods of treating a tauopathy
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
MX2016008448A (es) Conjugados de var2csa-farmaco.
BR112013018352A2 (pt) composição de minociclina tópica e método
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
MY161601A (en) Films and compositions comprising the same
CL2013000069A1 (es) Compuestos derivados de heterociclos fusionados, moduladores s1p; composicion farmaceutica; y uso en enfermedades neurodegenerativas.
MX339243B (es) Derivados fusionados sustituidos de imidazol, composiciones farmaceuticas y metodos de uso de los mismos.
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
BR112012029824A2 (pt) métodos para o preparo de cloreto de glicopirrônio, cloreto de glicopirrônio, composição farmacêutica e uso de cloreto de glicopirrônio